Onxeo S.A. announced the establishment of a Scientific Advisory Board comprised of international experts in the fields of DNA Damage Response (DDR), DNA genetics and drug discovery. Professor Tomas Lindahl MD, FRS, FMedSci will serve as Chair of the Scientific Advisory Board. Scientific Advisory Board Members: Marie Dutreix, Ph.D., is Director of Research at the Centre for National Research in Science (CNRS) and the co-founder of DNA Therapeutics; Penny Jeggo, Ph.D., is a Professorial Fellow at the Genome Damage and Stability Centre (GDSC) of the School of Life Sciences at the University of Sussex in Brighton, England; Yves Pommier, M.D., Ph.D., has been with the US National Institutes of Health (NIH) since 1981. He is the Chief of the Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology of the NIH since 1981; Robert Bristow, M.D., PhD, FRCPC (Fellow of the Royal College of Physicians of Canada), was a Clinician-Scientist and Professor of the Departments of Radiation Oncology and Medical Biophysics at the University of Toronto and a Senior Scientist at the Princess Margaret Cancer Centre; Sebastian Amigorena, Ph.D. heads the Immunology Department at the Institut Curie; and Josef Jiricny, Ph.D., is Professor Emeritus at the Institute of Biochemistry of the Swiss Federal Institute of Technology (ETH) in Zurich.